22:50 , Nov 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: B cell lymphoma Cell and mouse studies suggest promoting PMAIP1 expression or inhibiting MCL1 could enhance the efficacy of BCL-2 inhibitors to treat diffuse large B cell lymphoma (DLBCL). In a DLBCL cell line,...
20:43 , Nov 6, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Adenocarcinoma Mouse studies suggest dual inhibition of MCL1 and MEK could help treat KRAS-mutant adenocarcinoma. In seven patient-derived xenograft (PDX) mouse models of KRAS-mutant adenocarcinoma, the MCL1 inhibitor AMG 176 plus the MEK inhibitor...
19:12 , Feb 21, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Non-small cell lung cancer (NSCLC) Cell culture and mouse studies suggest combining MCL1 inhibitors with inducers of double-strand break stress could help treat NSCLC. In an irradiated human NSCLC cell line, MCL1 knockout decreased...
00:39 , Jan 31, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute lymphoblastic leukemia (ALL); multiple myeloma (MM)...
19:14 , Aug 22, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest inhibiting MCL1 could help treat triple-negative breast cancer (TNBC) and HER2 -amplified breast cancer. In breast cancer patient samples, levels of MCL1 were higher...
14:16 , Nov 30, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML); lymphoma; multiple myeloma (MM)...
07:00 , Sep 22, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Myeloid leukemia cell differentiation protein (MCL1); eukaryotic translation initiation factor 4B (EIF4B)

Cancer INDICATION: Breast cancer Patient sample and cell studies suggest inhibiting EIF4B or MCL1 could help treat basal breast cancer. In tumor samples from breast cancer patients, MCL1 levels were higher in the aggressive basal...